CALCIMEDICA INC (CALC) Stock Price & Overview
NASDAQ:CALC • US38942Q2021
Current stock price
The current stock price of CALC is 0.5882 USD. Today CALC is up by 8.93%. In the past month the price decreased by -5.74%. In the past year, price decreased by -67.68%.
CALC Key Statistics
- Market Cap
- 9.258M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.01
- Dividend Yield
- N/A
CALC Stock Performance
CALC Stock Chart
CALC Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CALC. When comparing the yearly performance of all stocks, CALC is a bad performer in the overall market: 98.92% of all stocks are doing better.
CALC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CALC. CALC has a bad profitability rating. Also its financial health evaluation is rather negative.
CALC Earnings
CALC Forecast & Estimates
10 analysts have analysed CALC and the average price target is 10.54 USD. This implies a price increase of 1691.91% is expected in the next year compared to the current price of 0.5882.
CALC Groups
Sector & Classification
CALC Financial Highlights
Over the last trailing twelve months CALC reported a non-GAAP Earnings per Share(EPS) of -2.01. The EPS decreased by -63.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -217.51% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CALC Ownership
CALC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.31 | 900.456B | ||
| JNJ | JOHNSON & JOHNSON | 20.96 | 587.99B | ||
| MRK | MERCK & CO. INC. | 23.35 | 298.764B | ||
| PFE | PFIZER INC | 9.56 | 162.403B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.75 | 125.711B | ||
| ZTS | ZOETIS INC | 16.57 | 49.512B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 27.972B | ||
| VTRS | VIATRIS INC | 5.43 | 15.693B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.98 | 11.495B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.787B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.274B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.606B | ||
| CORT | CORCEPT THERAPEUTICS INC | 50.81 | 4.465B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CALC
Company Profile
CalciMedica, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 16 full-time employees. The company went IPO on 2020-09-25. The firm focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The firm's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The firm is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
Company Info
IPO: 2020-09-25
CALCIMEDICA INC
505 Coast Boulevard South, Suite 307
La Jolla CALIFORNIA US
Employees: 16
Phone: 18589525500
CALCIMEDICA INC / CALC FAQ
What does CALCIMEDICA INC do?
CalciMedica, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in La Jolla, California and currently employs 16 full-time employees. The company went IPO on 2020-09-25. The firm focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The firm's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The firm is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
What is the stock price of CALCIMEDICA INC today?
The current stock price of CALC is 0.5882 USD. The price increased by 8.93% in the last trading session.
Does CALCIMEDICA INC pay dividends?
CALC does not pay a dividend.
How is the ChartMill rating for CALCIMEDICA INC?
CALC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for CALC stock?
CALCIMEDICA INC (CALC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.01).
What is the market capitalization of CALC stock?
CALCIMEDICA INC (CALC) has a market capitalization of 9.26M USD. This makes CALC a Nano Cap stock.